18F-FES PET/CT in Imaging Patients With Desmoid Tumors

• Status: Terminated
• Trial end date: 2017-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This pilot clinical trial studies fluorine (F)-18 16 alpha-fluoroestradiol (18F-FES) positron emission tomography (PET)/computed tomography (CT) in imaging patients with desmoid tumors. 18F-FES binds to estrogen receptors, which are present on desmoid tumors, and gives off radiation that may be detected by PET and CT scans. The PET/CT scan forms an image that may show where tumor cells with estrogen receptors can be found in the body.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Vanderbilt-Ingram Cancer Center
• Collaborator: National Cancer Institute (NCI)
• Treatments: Estradiol

Criteria

Inclusion Criteria:

• Patients with biopsy-proven extra-abdominal desmoid tumors

• Not currently on estrogen medication for birth control, menopause, or other reason

• No anti-estrogen therapy for desmoid tumor within the past 6 months

• Both sporadic desmoid tumors and those associated with familial adenomatous polyposis (FAP) syndromes will be included

Exclusion Criteria:

• Pregnancy or nursing patients

• Patients who do not wish to participate